| DIRECT COMPETITOR COMPARISON | |
| GNVC | Pvt1 | BIIB | MRK | Industry | | Market Cap: | 106.32M | N/A | 13.57B | 76.54B | 100.26M | | Employees: | 98 | N/A | 4,700 | 55,200 | 65 | | Qtrly Rev Growth (yoy): | -30.40% | N/A | 2.50% | 1.80% | 19.70% | | Revenue (ttm): | 13.83M | 1.30M1 | 4.32B | 23.37B | 14.05M | | Gross Margin (ttm): | -96.75% | N/A | 91.12% | 76.36% | 65.67% | | EBITDA (ttm): | -18.95M | N/A | 1.68B | 7.81B | -12.30M | | Oper Margins (ttm): | -144.06% | N/A | 28.43% | 26.63% | -137.11% | | Net Income (ttm): | -20.47M | -23.00M1 | 869.75M | 8.05B | N/A | | EPS (ttm): | -0.221 | N/A | 2.988 | 3.808 | -0.32 | | P/E (ttm): | N/A | N/A | 15.70 | 9.53 | 16.37 | | PEG (5 yr expected): | N/A | N/A | 1.37 | 2.18 | 1.31 | | P/S (ttm): | 7.84 | N/A | 3.18 | 3.30 | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | MRK | | Increase In Patent Protection For Biologics Creates Significant Upside For Drug Development Enterprise Valuations
Sat 10:31am -
Wall Street Transcript | | • | BIIB | | Biotech Bargains for Your Portfolio
Fri, Nov 27 -
at Motley Fool | | • | MRK | | 3 Stocks Springing Back
Fri, Nov 27 -
at Motley Fool | | • | MRK | | 3 China Profit Plays
Fri, Nov 27 -
at Motley Fool | | • | MRK | | INSIDE WASHINGTON: Stream of WH health care visits
Thu, Nov 26 -
AP | | • | MRK | | Zetia's Miraculous Popularity
Thu, Nov 26 -
at Forbes.com | | • | BIIB | | Financing Drug Discovery: Recent Deals
Thu, Nov 26 -
at Seeking Alpha | | • | BIIB | | Cancer drug preserves insulin cells in diabetes
Wed, Nov 25 -
at Reuters | | • | BIIB | | Still Enjoying Those Acquisitions, Pfizer?
Wed, Nov 25 -
at Motley Fool | | • | BIIB | | InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
Wed, Nov 25 -
GlobeNewswire | | • | BIIB | | [$$] Fitz Bits: Wait for a Retest in Ford
Mon, Nov 23 -
at RealMoney by TheStreet.com | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
